VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Unmet needs in high-risk MDS and ongoing trials in the field

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, highlights some unmet needs in high-risk myelodysplastic syndromes (HR-MDS), drawing focus on the need to improve treatment combinations with azacitidine and ongoing trials evaluating these combinations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter